Changes in Treatment Approach
There are limited data
for sequencing post
immune checkpoint
inhibitor treatments
for highly refractory RCC patients
Sequencing and combining treatments requires consideration of overlapping class effects, strategically withholding drugs, alternating therapeutic classes, washout periods, and other variables and approaches9,14,21
Myriad factors to consider
As data evolve, tolerability and target selectivity represent important considerations in sequencing treatment decisions. Within the VEGFRi class, which includes target-specific and -nonspecific drugs, agents may be differentiated by their5,6,22-24: